Dr. Falbo concentrates her practice on U.S. and foreign patent drafting and prosecution, as well as global portfolio management for the life science, pharmaceutical, and biotechnology industries.
Building on her technical prowess in cellular and molecular biology and cancer biology, Dr. Falbo has experience managing patent portfolios in the areas of immunotherapies and cellular therapies, including T-cell therapies, Natural Killer cell-based therapies, and stem cell therapies; protein therapeutics, including antibody and protein-based therapies; gene-based therapies, including CRISPR; virus therapies; and diagnostic assays and bioassays.
Before joining Baker Donelson, Dr. Falbo worked as a patent agent and scientific advisor in the life sciences patent groups of several law firms and gained extensive hands-on research experience as a researcher at MD Anderson Cancer Center and other research institutions.
Dr. Falbo received her Ph.D. in Cancer Molecular Biology from The University of Texas – MD Anderson Cancer Center Graduate School of Biomedical Sciences, where she identified and described a new role for the INO80 chromatin-remodeling complex in DNA replication related damage and cancer development. The results of her research have been published in peer-reviewed scientific journals, and she has presented her results at national scientific meetings.
Dr. Falbo is fluent in both English and Spanish.